Bvf Cut Its Concert Pharmaceuticals (CNCE) Stake by $828,652 as Share Price Declined; Harvey Partners Has Lowered Stake in Entegris (ENTG) by $2.38 Million

June 14, 2018 - By Henry Gaston

Entegris, Inc. (NASDAQ:ENTG) Logo

Bvf Inc decreased its stake in Concert Pharmaceuticals Inc (CNCE) by 1.91% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 37,666 shares as the company’s stock declined 9.58% with the market. The hedge fund held 1.93M shares of the health care company at the end of 2018Q1, valued at $44.25 million, down from 1.97 million at the end of the previous reported quarter. Bvf Inc who had been investing in Concert Pharmaceuticals Inc for a number of months, seems to be less bullish one the $455.28M market cap company. The stock increased 1.14% or $0.22 during the last trading session, reaching $19.46. About 56,107 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 41.24% since June 14, 2017 and is uptrending. It has outperformed by 28.67% the S&P500. Some Historical CNCE News: 07/05/2018 – Concert Pharma at Deutsche Bank Health Care Conference Tomorrow; 02/04/2018 – Concert Pharma Closes Below 50-Day Moving Average: Technicals; 10/04/2018 – CONCERT PHARMACEUTICALS: INTER PARTES REVIEW FILED BY INCYTE; 21/03/2018 – PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO D; 03/05/2018 – Concert Pharma Closes Above 200-Day Moving Average: Technicals; 25/04/2018 – Concert Pharmaceuticals: Topline Phase 2a Data From the 4 Mg and 8 Mg Cohorts Expected in Fourth Qtr of 2018; 15/05/2018 – Ghost Tree Capital Buys New 1.5% Position in Concert Pharma; 03/05/2018 – Concert Pharmaceuticals Cash, Cash Equivalents and Investments at March 31 Totaled $191M; 03/05/2018 – Concert Pharmaceuticals Expects Cash, Cash Equivalents and Investments as of March 31, 2018 to Be Sufficient to Fund the Co Into 2021; 25/04/2018 – CONCERT PHARMACEUTICALS INC – PHASE 2B CLINICAL TRIAL EVALUATING CTP-543 IS EXPECTED TO BEGIN IN 2019




Jeffrey Moskowitz decreased its stake in Entegris Inc (ENTG) by 42.42% based on its latest 2018Q1 regulatory filing with the SEC. Harvey Partners Llc sold 70,000 shares as the company’s stock rose 1.02% while stock markets declined. The hedge fund run by Jeffrey Moskowitz held 95,000 shares of the consumer non-durables company at the end of 2018Q1, valued at $3.31M, down from 165,000 at the end of the previous reported quarter. Harvey Partners Llc who had been investing in Entegris Inc for a number of months, seems to be less bullish one the $5.48 billion market cap company. The stock decreased 0.06% or $0.03 during the last trading session, reaching $38.67. About 245,985 shares traded. Entegris, Inc. (NASDAQ:ENTG) has risen 43.69% since June 14, 2017 and is uptrending. It has outperformed by 31.12% the S&P500. Some Historical ENTG News: 09/04/2018 – Entegris Closes Above 50-Day Moving Average: Technicals; 26/04/2018 – Entegris Reports Record Sales and Earnings in First Quarter of 2018; 26/04/2018 – Entegris 1Q Net $57.6M; 20/04/2018 – DJ Entegris Inc, Inst Holders, 1Q 2018 (ENTG); 29/03/2018 – Praxair Technology, Inc. vs Entegris, Inc. | FWD Entered | 03/29/2018; 03/05/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within NetScout, Entegris, Pinnacle Entertainment, First Foundatio; 26/04/2018 – Entegris 1Q EPS 40c; 30/05/2018 – Resonant Appoints Industry Veteran Marybeth Carberry as Vice President, Business Operations; 01/05/2018 – Entegris to Participate in the Barclays Electronic Chemicals Conference

Since January 16, 2018, it had 0 buys, and 6 insider sales for $2.60 million activity. On Tuesday, April 17 Cassella James V sold $213,510 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 10,582 shares.

Bvf Inc, which manages about $999.89 million and $986.48 million US Long portfolio, upped its stake in Verastem Inc (NASDAQ:VSTM) by 487,000 shares to 2.74M shares, valued at $8.16 million in 2018Q1, according to the filing. It also increased its holding in Pieris Pharmaceuticals Inc by 968,987 shares in the quarter, for a total of 3.59 million shares, and has risen its stake in Immune Design Corp (NASDAQ:IMDZ).

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 25 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was initiated by Aegis Capital on Wednesday, September 9 with “Buy”. H.C. Wainwright maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Wednesday, August 9 with “Buy” rating. H.C. Wainwright maintained the shares of CNCE in report on Friday, March 2 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Friday, November 10. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Tuesday, September 22 by TH Capital. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Neutral” rating by UBS on Monday, November 9. The rating was downgraded by Mizuho on Friday, January 12 to “Neutral”. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Friday, May 4. On Friday, March 9 the stock rating was upgraded by Mizuho to “Buy”.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on August, 14. They expect $-0.62 earnings per share, down 6.90% or $0.04 from last year’s $-0.58 per share. After $-0.19 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 226.32% negative EPS growth.

Investors sentiment decreased to 1.37 in Q1 2018. Its down 1.25, from 2.62 in 2017Q4. It is negative, as 13 investors sold CNCE shares while 33 reduced holdings. 29 funds opened positions while 34 raised stakes. 16.64 million shares or 7.42% more from 15.49 million shares in 2017Q4 were reported. The California-based Lyon Street Cap Lc has invested 0.09% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Dimensional Fund Advisors LP reported 737,646 shares or 0.01% of all its holdings. 3,172 were reported by Legal And General Gru Public Ltd. Svcs Automobile Association reported 32,233 shares. 21,895 were reported by Deutsche Retail Bank Ag. Ameritas Invest Ptnrs holds 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 1,527 shares. Element Cap Mngmt Ltd Limited Liability Company owns 25,363 shares for 0.01% of their portfolio. Parametric Port Assoc reported 0% stake. Moreover, Riverhead Cap Mngmt Ltd has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 196 shares. 2,419 are held by Zurcher Kantonalbank (Zurich Cantonalbank). Knott David M has 0.47% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 49,557 shares. Bvf Il reported 4.49% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Northern Trust reported 636,097 shares. California Employees Retirement Systems reported 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Metropolitan Life Comm New York holds 6,348 shares or 0% of its portfolio.

Harvey Partners Llc, which manages about $369.32M and $67.61M US Long portfolio, upped its stake in Koppers Holdings Inc (NYSE:KOP) by 48,000 shares to 98,000 shares, valued at $4.03 million in 2018Q1, according to the filing.

Another recent and important Entegris, Inc. (NASDAQ:ENTG) news was published by Seekingalpha.com which published an article titled: “Entegris, Inc. (ENTG) Entegris Announces Agreement to Acquire SAES Pure Gas Business Conference (Transcript)” on June 07, 2018.

Investors sentiment decreased to 0.91 in 2018 Q1. Its down 0.39, from 1.3 in 2017Q4. It fall, as 20 investors sold ENTG shares while 96 reduced holdings. 38 funds opened positions while 67 raised stakes. 129.26 million shares or 1.23% less from 130.87 million shares in 2017Q4 were reported. Jpmorgan Chase And Co holds 1.30 million shares. Susquehanna Group Llp reported 7,524 shares. Captrust has 0% invested in Entegris, Inc. (NASDAQ:ENTG). Washington-based Parametric Portfolio Assoc Llc has invested 0.01% in Entegris, Inc. (NASDAQ:ENTG). Redwood Invests Llc invested 1.74% of its portfolio in Entegris, Inc. (NASDAQ:ENTG). Clarivest Asset Mngmt Ltd Liability Corp owns 0.12% invested in Entegris, Inc. (NASDAQ:ENTG) for 204,210 shares. The New York-based Silvercrest Asset Ltd has invested 0.62% in Entegris, Inc. (NASDAQ:ENTG). Pub Employees Retirement Sys Of Ohio has invested 0.04% in Entegris, Inc. (NASDAQ:ENTG). Reliance Trust Of Delaware holds 0.04% of its portfolio in Entegris, Inc. (NASDAQ:ENTG) for 6,641 shares. Alphaone Inv Services Ltd Liability Corp owns 950 shares. Acadian Asset Mngmt Limited Company accumulated 0% or 26,507 shares. 155,921 were reported by Rafferty Asset Management Ltd Llc. Thompson Davis And Co reported 0.02% in Entegris, Inc. (NASDAQ:ENTG). Ubs Asset Americas accumulated 95,174 shares. State Board Of Administration Of Florida Retirement Systems owns 114,032 shares.

Since February 20, 2018, it had 0 insider purchases, and 8 insider sales for $10.34 million activity. The insider GRAVES GREGORY B sold $1.90 million. LOY BERTRAND sold $5.86 million worth of stock or 175,000 shares. Shaner William James also sold $333,312 worth of Entegris, Inc. (NASDAQ:ENTG) shares. $338,485 worth of Entegris, Inc. (NASDAQ:ENTG) shares were sold by Rucci Corey. Shares for $252,236 were sold by Edlund Todd James on Thursday, March 8.

Among 13 analysts covering Entegris (NASDAQ:ENTG), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Entegris had 32 analyst reports since August 3, 2015 according to SRatingsIntel. Loop Capital maintained the stock with “Buy” rating in Friday, October 27 report. The stock of Entegris, Inc. (NASDAQ:ENTG) earned “Buy” rating by Needham on Friday, June 8. Stifel Nicolaus maintained Entegris, Inc. (NASDAQ:ENTG) on Thursday, July 13 with “Buy” rating. The rating was upgraded by Needham on Monday, March 13 to “Buy”. The firm earned “Buy” rating on Tuesday, February 6 by Stifel Nicolaus. Dougherty & Company upgraded it to “Buy” rating and $20 target in Thursday, October 27 report. On Friday, February 3 the stock rating was maintained by Dougherty & Company with “Buy”. The stock of Entegris, Inc. (NASDAQ:ENTG) has “Hold” rating given on Monday, November 21 by Needham. As per Wednesday, March 21, the company rating was maintained by Craig Hallum. The rating was maintained by Needham on Thursday, October 19 with “Buy”.

Entegris, Inc. (NASDAQ:ENTG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.